CompoAtlas

Pamidrol Osteoarthritis

Natural health product licensed in Canada

Other names
Osteoarthritis Pain Relief
Licence holder
Kreda Neuroplastic Alternatives Inc.
NPN or DIN-HM
80128462
Status
Active licence
Licence date
8 December 2023
Revision date
29 January 2024
Form
Capsule
Route of administration
Orale
Application type
Générale (non traditionelle)

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Zinc

Source : Citrate de zinc

25 mg50,000 µg
Calcium

Source : Carbonate de calcium

36 mg72,000 µg
Vitamine D

Source : Cholécalciférol

500 UI25 µg
Vitamine D

Source : Cholécalciférol

0.0125 mg25 µg
N-(2-Hydroxyéthyl)hexadécanamide

Source : Palmitoyléthanolamide

500 mgNot calculated
2-(3,4-dihydroxyphényl)-5,7-dihydroxy-4-benzopyrone

Source : Bacopa monnieri - Sommité (herbe)

10 mgNot calculated

Non-medicinal ingredients

Cellulose microcristalline, Stéarate de magnésium, Hypromellose

PopulationAgeQuantity per servingFrequency
Adultesminimum: 18 years1 Capsule2 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may help prevent bone loss/osteoporosis (in peri- and postmenopausal women) (in later life). As part of a healthy diet (when taken with Vitamin D) may help prevent bone loss/osteoporosis. Vitamin D intake, when combined with sufficient calcium, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. Helps relieve minor pain associated with osteoarthritis.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80128462

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2024. Photograph the packaging to check whether it has changed. Photograph the packaging

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line